An Exploratory Trial of Dalpiciclib in Combination With Endocrine Therapy in HR-positive / HER2-negative Advanced Breast Cancer Patients With Visceral Crisis

This is a multicenter, single-arm, open-label, Simon's two-stage exploratory clinical trial. 18 eligible patients with advanced breast cancer with visceral crisis will enroll in stage I. If the study enter stage 2 and continue to include 53 assessable subjects (35 in stage 2). All eligible patients will receive Dalpiciclib plus endocrine therapy chosen by the Physicians until disease progression, death or intolerable toxicity. Tumor assessment was conducted according to RECIST 1.1 criteria.

Start Date01 Jun 2022

Sponsor / Collaborator

Jiangsu Hengrui Pharmaceuticals Co., Ltd.

CTRI/2020/03/024375 / Not yet recruitingNot ApplicableIIT

Effect of Duration of Preoperative Fasting on the Incidence of Emergence Delerium in Paediatric Patients during Recovery From General Anaesthesia:A Randomized Controlled Trial

Start Date01 Apr 2020

Sponsor / Collaborator-

100 Clinical Results associated with Visceral spasms

100 Translational Medicine associated with Visceral spasms

0 Patents (Medical) associated with Visceral spasms

405

Literatures (Medical) associated with Visceral spasms

01 Jun 2024·Geburtshilfe und Frauenheilkunde

Update Breast Cancer 2024 Part 1 – Expert Opinion on Advanced Breast Cancer

Article

Author: Wöckel, Achim ; Witzel, Isabell ; Taran, Florin-Andrei ; Kolberg, Hans-Christian ; Fehm, Tanja N ; Hörner, Manuel ; Lux, Michael P ; Janni, Wolfgang ; Stickeler, Elmar ; Müller, Volkmar ; Ditsch, Nina ; Würstlein, Rachel ; Aktas, Bahriye ; Schütz, Florian ; Bartsch, Rupert ; Untch, Michael ; Harbeck, Nadia ; Tesch, Hans ; Thomssen, Christoph ; Ettl, Johannes ; Krückel, Annika ; Krug, David ; Welslau, Manfred ; Lüftner, Diana ; Hartkopf, Andreas D ; Banys-Paluchowski, Maggie ; Schneeweiss, Andreas ; Thill, Marc ; Belleville, Erik ; Fasching, Peter A

AbstractClinical evidence is interpreted based on clinical studies and personal experience which can lead to different interpretations of data. This makes the opinions issued by panels of experts such as the Advanced Breast Cancer Panel which convened in November 2023 for the seventh time (ABC7) particularly important. At the conference, current issues around advanced breast cancer were evaluated by an international team of experts.In 2023 the data on CDK4/6 inhibitors was so extensive that the answers to questions about the sequencing of therapy and the potential use of chemotherapy as an alternative therapy were relatively clear. Moreover, data on antibody drug conjugates which provides a good overview of their uses is available for all molecular subtypes.Some therapeutic settings, including patients with brain metastases or leptomeningeal disease, older patients, locally advanced breast cancer and visceral crises, continue to be particularly important and were discussed in structured sessions. The scientific context of some of the topics discussed at ABC7 is presented and assessed here.

18 May 2024·Journal of Chemotherapy

Case series of metastatic breast cancer patients with visceral crisis treated with CDK4/6 inhibitors

Article

Author: Tjan-Heijnen, Vivianne C. G. ; Dercksen, M. Wouter ; Geurts, Sandra M. E. ; Meegdes, Marissa ; van der Velde, Marleen G. A. M. ; van Kats, Maartje A. C. E.

There is an ongoing clinical dilemma of how best to treat patients who present themselves with visceral crisis. The time needed to undo the state of visceral crisis is the most relevant outcome for this patient group. We describe four patients treated with CDK4/6 inhibitor plus endocrine therapy for HR+/HER2- metastatic breast cancer who presented themselves with a visceral crisis. Two of them are male and three of them had synchronous metastatic breast cancer. Two patients had lymphangitis carcinomatosis of the lungs, one extensive disease of the eye and one of the liver. Time to first clinical response was observed within a few weeks in three patients. For one patient a switch to chemotherapy was needed. These cases show that treatment with CDK4/6 inhibitors can achieve a rapid response in patients experiencing visceral crisis. We conclude that chemotherapy is not the sole possibility in visceral crisis, and that CDK4/6 inhibitors can be considered as well.

04 Feb 2024·Frontiers in Bioscience-Landmark

Calcium Channel Inhibitory Effect of Marjoram (Origanum majorana L.): Its Medicinal Use in Diarrhea and Gut Hyperactivity

Article

Author: Ahmad, Wasim ; Rehman, Najeeb Ur ; Ansari, Mohd Nazam ; Ali, Abuzer

BACKGROUNDThe leaves of Origanum majorana (O. majorana) are traditionally renowned for treating diarrhea and gut spasms. This study was therefore planned to evaluate its methanolic extract.METHODSGas chromatography-mass spectrometry (GC-MS) was used to identify the phytochemicals, and Swiss albino mice were used for an in vivo antidiarrheal assay. Isolated rat ileum was used as an ex vivo assay model to study the possible antispasmodic effect and its mechanism(s).RESULTSThe GC-MS analysis of O. majorana detected the presence of 21 compounds, of which alpha-terpineol was a major constituent. In the antidiarrheal experiment, O. majorana showed a substantial inhibitory effect on diarrheal episodes in mice at an oral dosage of 200 mg/kg, resulting in 40% protection. Furthermore, an oral dosage of 400 mg/kg provided even greater protection, with 80% effectiveness. Similarly, loperamide showed 100% protection at oral doses of 10 mg/kg. O. majorana caused complete inhibition of carbachol (CCh, 1 µM) and high K+ (80 mM)-evoked spasms in isolated ileal tissues by expressing significantly higher potency (p < 0.05) against high K+ compared to CCh, similar to verapamil, a Ca++ antagonist. The verapamil-like predominant Ca++ ion inhibitory action of O. majorana was further confirmed in the ileal tissues that were made Ca++-free by incubating the tissues in a physiological salt solution having ethylenediaminetetraacetic acid (EDTA) as a chelating agent. The preincubation of O. majorana at increasing concentrations (0.3 and 1 mg/mL) shifted towards the right of the CaCl2-mediated concentration-response curves (CRCs) with suppression of the maximum contraction. Similarly, verapamil also caused non-specific suppression of Ca++ CRCs towards the right, as expected.CONCLUSIONSThus, this study conducted an analysis to determine the chemical constituents of the leaf extract of O. majorana and provided a detailed mechanistic basis for the medicinal use of O. majorana in hyperactive gut motility disorders.

Analysis

Perform a panoramic analysis of this field.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

Visceral spasms

Basic Info

Related

Analysis